<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341962</url>
  </required_header>
  <id_info>
    <org_study_id>P2-IMU-838-UC</org_study_id>
    <secondary_id>P2-IMU-838-UC</secondary_id>
    <secondary_id>2017-003703-22</secondary_id>
    <nct_id>NCT03341962</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose-finding IMU-838 for Ulcerative Colitis</brief_title>
  <acronym>CALDOSE-1</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunic AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunic AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding&#xD;
      study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy&#xD;
      with an option for open-label treatment extension in moderate-to-severe ulcerative colitis&#xD;
      (CALDOSE-1).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigational medicinal product (IMP) IMU-838 (vidofludimus calcium) is a new compound&#xD;
      that selectively inhibits the human enzyme dihydroorotate dehydrogenase (DHODH).&#xD;
      Dihydroorotate dehydrogenase plays a major role in the de-novo pyrimidine synthesis and is&#xD;
      specifically expressed at high levels in proliferating or activated lymphocytes. Resting&#xD;
      lymphocytes satisfy their pyrimidine requirements through a DHODH-independent salvage&#xD;
      pathway. Thus, IMU-838-mediated DHODH inhibition selectively affects activated, rapidly&#xD;
      proliferating lymphocytes. The metabolic stress secondary to DHODH inhibition leads to a&#xD;
      reduction of pro-inflammatory cytokine release including interleukin (IL)-17 (IL-17A and&#xD;
      IL-17F) and interferon gamma (IFNÎ³), and to an increased apoptosis in activated lymphocytes.&#xD;
&#xD;
      This is a phase 2, multicenter, randomized, double-blind, and placebo-controlled trial in&#xD;
      patients with moderate-to-severe UC with an option for open-label treatment extension. The&#xD;
      study comprises a blinded induction phase to establish the optimal dose of IMU-838 to induce&#xD;
      response and remission, a blinded maintenance phase to evaluate the potential of IMU-838 to&#xD;
      maintain remission until Week 50, and an open-label treatment extension arm for all patients&#xD;
      who discontinue the blinded phase as scheduled or prematurely, subject to certain&#xD;
      restrictions. A subset of patients will undergo a pharmacokinetic (PK) period at the start of&#xD;
      the open-label period to establish a full single-dose PK profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic remission and endoscopic healing</measure>
    <time_frame>Week 10</time_frame>
    <description>Composite endpoint: Proportion of patients with both, symptomatic remission and endoscopic healing at Week 10.&#xD;
All patients (both, Enrollment Period 1 and Enrollment Period 2 patients) who were randomized to 30 mg/day and 45 mg/day will be used for the assessment of the primary efficacy endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic remission and endoscopic healing at different doses</measure>
    <time_frame>Week 10</time_frame>
    <description>Proportion of patients with both symptomatic remission and endoscopic healing at Week 10&#xD;
(all individual IMU-838 doses will be compared with one another and to placebo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic remission during induction</measure>
    <time_frame>22 weeks</time_frame>
    <description>Proportion of patients achieving symptomatic remission during the induction phase (including extended induction phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieving symptomatic remission</measure>
    <time_frame>22 weeks</time_frame>
    <description>Time to achieving symptomatic remission within the induction/extended induction phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical response</measure>
    <time_frame>10 weeks</time_frame>
    <description>Proportion of patients with clinical response at Week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with endoscopic healing</measure>
    <time_frame>Week 10</time_frame>
    <description>Proportion of patients with endoscopic healing at Week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with symptomatic response</measure>
    <time_frame>22 weeks</time_frame>
    <description>Proportion of patients with symptomatic response during the induction phase (including extended induction phase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full Mayo Score</measure>
    <time_frame>Week 10</time_frame>
    <description>Change in full Mayo Score compared to baseline at Week 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Mayo Score</measure>
    <time_frame>Up to Week 22</time_frame>
    <description>Change in partial mayo score over 10 or 22 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO)-2 Mayo Score</measure>
    <time_frame>Up to Week 22</time_frame>
    <description>Change in PRO-2 mayo score over 10 or 22 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin (fCP)</measure>
    <time_frame>Changes from Baseline over 10 or 22 weeks</time_frame>
    <description>Change in the presence of biomarker fCP in stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>Changes from Baseline over 10 or 22 weeks</time_frame>
    <description>Change in the presence of biomarker CRP in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Events</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Incidence and Severity of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of participants with clinically significant findings during physical examination</measure>
    <time_frame>up to Week 50</time_frame>
    <description>The emergence of any clinically significant findings compared to screening will be captured during the induction and maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: body weight</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Changes in body weight during the induction and maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: blood pressure</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Changes in blood pressure (mm Hg) during the induction and maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: heart rate</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Changes in heart rate (beats per minute) during the induction and maintenance phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: 12-lead electrocardiogram (ECG)</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of patients with clinically significant changes in ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Hematology</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of participants with abnormal hematology laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Blood Chemistry</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of participants with abnormal blood chemistry laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Coagulation</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of participants with abnormal coagulation laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Urinalysis</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Number of participants with abnormal urinalysis laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Micro ribonucleic acid expression</measure>
    <time_frame>pre-dose and 24 hours post-dose</time_frame>
    <description>Micro ribonucleic acid-122 (miR-122) expression (before first dose and 24 hours after first dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: IMU-838 trough level</measure>
    <time_frame>up to Week 10</time_frame>
    <description>Measurement of pre-dose (trough) blood plasma levels of IMU-838 throughout the induction period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: IMU-838 plasma level</measure>
    <time_frame>Week 2</time_frame>
    <description>Measurement of post-dose blood plasma levels of IMU-838 at Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: area under the drug concentration-time curve (AUC) from time zero to 24 hours (AUC0-24h)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of AUC0-24h in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC time zero to last measurable concentration (AUC0-t)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of AUC0-t in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC time zero to infinity (AUC0-inf)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of AUC0-inf in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: maximum plasma concentration (Cmax)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of Cmax in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: time to Cmax (Tmax)</measure>
    <time_frame>pre-dose, 1, 2, 3, 4, 5, 6 hours post PK dose; 24 hours post PK dose; 48 hours post PK dose; 72 hours post PK dose</time_frame>
    <description>Single-dose PK measurement of Tmax in a subset of patients in the open-label phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Proportion of patients with symptomatic response</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Proportion of patients in symptomatic remission by visit up to Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Mayo PRO-2 score</measure>
    <time_frame>Week 50</time_frame>
    <description>Time course of Mayo PRO-2 score until Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Time to relapse</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Time to symptomatic ulcerative colitis (UC) relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Proportion of patients without relapse</measure>
    <time_frame>Week 50</time_frame>
    <description>Proportion of patients without symptomatic UC relapse until Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: fCP</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Change in the presence of biomarker fCP in stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: CRP</measure>
    <time_frame>up to Week 50</time_frame>
    <description>Change in the presence of biomarker CRP in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Proportion of patients with endoscopic healing</measure>
    <time_frame>Week 50</time_frame>
    <description>Proportion of patients with endoscopic healing at Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: Proportion of patients with microscopic healing</measure>
    <time_frame>Week 50</time_frame>
    <description>Proportion of patients with microscopic healing at Week 50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance Phase: corticosteroid-free remission</measure>
    <time_frame>Week 50</time_frame>
    <description>Corticosteroid-free remission at Week 50 in patients receiving corticosteroids at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-label Phase: symptom control</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Proportion of patients with symptom control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-label Phase: fCP</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Change in the presence of biomarker fCP in stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Open-label Phase: CRP</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Change in the presence of biomarker fCP in blood samples</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>10 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.&#xD;
Patients will receive only half of their assigned full dose during the first week of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 15 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.&#xD;
Patients will receive only half of their assigned full dose during the first week of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 22.5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.&#xD;
Patients will receive only half of their assigned full dose during the first week of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (during induction)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg IMU-838 (Maintenance)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 5 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg IMU-838 (Maintenance)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 15 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (during maintenance)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg IMU-838 (Open-label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 15 mg tablets once daily of IMU-838 for up to 10 years and up to 3 years in UK sites</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMU-838</intervention_name>
    <description>IMU-838 tablet</description>
    <arm_group_label>10 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_label>10 mg IMU-838 (Maintenance)</arm_group_label>
    <arm_group_label>30 mg IMU-838 (Induction)</arm_group_label>
    <arm_group_label>30 mg IMU-838 (Maintenance)</arm_group_label>
    <arm_group_label>30 mg IMU-838 (Open-label)</arm_group_label>
    <arm_group_label>45 mg IMU-838 (Induction)</arm_group_label>
    <other_name>IM90838</other_name>
    <other_name>vidofludimus calcium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets manufactured to mimic IMU-838 tablets</description>
    <arm_group_label>placebo (during induction)</arm_group_label>
    <arm_group_label>placebo (during maintenance)</arm_group_label>
    <other_name>Placebo (for IMU-838)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        Induction phase&#xD;
&#xD;
          1. Male and female patients, aged 18 - 80 years&#xD;
&#xD;
          2. UC diagnosed more than 3 months before Screening (Day-30) as documented in the medical&#xD;
             chart&#xD;
&#xD;
          3. Previous treatment failure defined as:&#xD;
&#xD;
               1. Patient had an inadequate response with, lost response to, or was intolerant to&#xD;
                  approved or experimental immunomodulators (azathioprine, 6-mercaptopurine,&#xD;
                  6-thioguanine, methotrexate, or tofacitinib) or biologics (no more than 2&#xD;
                  treatment failures with biologic drugs i.e. anti-tumor necrosis factor Î±&#xD;
                  antibodies [infliximab, adalimumab, golimumab and their biosimilars],&#xD;
                  vedolizumab, or certain experimental antibodies [ustekinumab]); or&#xD;
&#xD;
               2. Patient had an inadequate response to, was intolerant to, or is corticosteroid&#xD;
                  dependent (corticosteroid-dependent patients are defined as i) unable to reduce&#xD;
                  steroids below the equivalent of prednisolone 10 mg/day within 3 months of&#xD;
                  starting steroids, without recurrent active disease, or ii) who have a relapse&#xD;
                  within 3 months of stopping steroids.)&#xD;
&#xD;
          4. Active disease defined as&#xD;
&#xD;
             a. Mayo stool frequency score of â¥2 at Screening Visit 1 b. Mayo rectal bleeding score&#xD;
             of â¥1 at Screening Visit 1 c. modified Mayo endoscopy subscore of â¥2 at the screening&#xD;
             flexible sigmoidoscopy (endoscopy assessed by an independent central reader blinded to&#xD;
             screening center and patient information)&#xD;
&#xD;
          5. Endoscopic appearance typical for UC and extending &gt;15 cm from the anal verge as&#xD;
             confirmed by an independent central reader (blinded to screening center and patient&#xD;
             information)&#xD;
&#xD;
          6. Laboratory values: Neutrophil count &gt;1500 cells/ÂµL, platelet count â¥100 000 /mm3,&#xD;
             serum creatinine &lt;1.5 x upper limit of normal (ULN), total bilirubin, alanine&#xD;
             aminotransferase (ALT), and gamma-glutamyl transferase (GGT) &lt;1.5 x ULN&#xD;
&#xD;
          7. Female patients must:&#xD;
&#xD;
             a. Be of non-child-bearing potential i.e. surgically sterilized (hysterectomy,&#xD;
             bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before Screening) or&#xD;
             post-menopausal (where postmenopausal is defined as no menses for 12 months without an&#xD;
             alternative medical cause), or&#xD;
&#xD;
             b. If of child-bearing potential, must have a negative pregnancy test at Screening&#xD;
             (blood test) and before the first study drug administration (Day 0 urine test). They&#xD;
             must agree not to attempt to become pregnant, must not donate ova, and must use a&#xD;
             highly effective contraceptive method 2 months before Screening, during treatment with&#xD;
             IMU-838, and at least 3 months after the last dose of study therapy&#xD;
&#xD;
             Highly effective forms of birth control are those with a failure rate less than 1% per&#xD;
             year and include:&#xD;
&#xD;
             - oral, intravaginal, or transdermal combined (estrogen and progestogen containing)&#xD;
             hormonal contraceptives associated with inhibition of ovulation&#xD;
&#xD;
               -  oral, injectable, or implantable progestogen-only hormonal contraceptives&#xD;
                  associated with inhibition of ovulation&#xD;
&#xD;
               -  intrauterine device or intrauterine hormone-releasing system&#xD;
&#xD;
               -  bilateral tubal occlusion&#xD;
&#xD;
               -  vasectomized partner (i.e. the patient's male partner has undergone effective&#xD;
                  surgical sterilization before the female patient entered the clinical trial and&#xD;
                  he is the sole sexual partner of the female patient during the clinical trial)&#xD;
&#xD;
               -  sexual abstinence (acceptable only if it is the patient's usual form of birth&#xD;
                  control/lifestyle choice) 8. Male patients must agree not to father a child or to&#xD;
                  donate sperm starting at Screening and throughout the clinical trial and for 3&#xD;
                  months after the last dose of study medication.&#xD;
&#xD;
          8. Male patients must also either&#xD;
&#xD;
             - abstain from sexual intercourse with a female partner (acceptable only if it is the&#xD;
             patient's usual form of birth control/lifestyle choice), or&#xD;
&#xD;
             - use adequate barrier contraception during treatment with IMU-383 and for at least 3&#xD;
             months after the last dose of study medication&#xD;
&#xD;
             For Poland and the UK the following additional requirement apply:&#xD;
&#xD;
               -  if male patients have a female partner of childbearing potential, the partner&#xD;
                  should use a highly effective contraceptive method as outlined in inclusion&#xD;
                  criterion 7&#xD;
&#xD;
             And additionally, for Poland only:&#xD;
&#xD;
               -  if male patients have a pregnant partner, they must use condoms while taking&#xD;
                  study medication to avoid exposure of the fetus to study medication&#xD;
&#xD;
          9. Ability to understand and comply with study procedures and restrictions&#xD;
&#xD;
         10. The patient is legally competent, has been informed of the nature, the scope and the&#xD;
             relevance of the study, voluntarily agrees to participation and the study's provisions&#xD;
             and has duly signed the informed consent form&#xD;
&#xD;
        Maintenance phase&#xD;
&#xD;
        1. Symptomatic remission achieved at Week 10 or Week 22 of the induction phase&#xD;
&#xD;
        Open-label treatment extension arm&#xD;
&#xD;
        1. Patient is in the induction phase, had received at least 6 weeks of blinded study&#xD;
        treatment and completed the sigmoidoscopy (incl. biopsy) regularly scheduled at Week 10/End&#xD;
        of Induction, and has neither reached symptomatic remission nor symptomatic response&#xD;
&#xD;
        OR&#xD;
&#xD;
        Patient is in the extended induction phase, had completed all Week 10 assessments, and has&#xD;
        not reached symptomatic remission during or at the end of the extended induction phase, Or&#xD;
        Patient is in the maintenance phase and discontinues from the maintenance phase due to&#xD;
        symptomatic UC relapse or other reasons with a flexible sigmoidoscopy performed at&#xD;
        discontinuation (if the previous sigmoidoscopy had been performed more than 4 weeks before&#xD;
        discontinuation)&#xD;
&#xD;
        OR&#xD;
&#xD;
        Patient has completed the maintenance phase as scheduled (including all Week 50&#xD;
        assessments)&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Gastrointestinal exclusion criteria&#xD;
&#xD;
          1. Diagnosis of Crohn's disease, inflammatory bowel disease type unclassified, ischemic&#xD;
             colitis, microscopic colitis, radiation colitis or diverticular disease-associated&#xD;
             colitis&#xD;
&#xD;
          2. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine&#xD;
&#xD;
          3. History of colectomy with ileorectal anastomosis or ileal-pouch anal anastomosis or&#xD;
             imminent need for colectomy (i.e. colectomy is being planned)&#xD;
&#xD;
          4. Active therapeutically uncontrollable abscess or toxic megacolon&#xD;
&#xD;
          5. Malabsorption or short bowel syndrome&#xD;
&#xD;
          6. History of colorectal cancer or colorectal dysplasia (with the exception of dysplasia&#xD;
             in polyps which have been removed)&#xD;
&#xD;
             Infectious disease exclusion criteria&#xD;
&#xD;
          7. Clostridium difficile (C. difficile) infection&#xD;
&#xD;
               -  Evidence of, or treatment for C. difficile infection within 30 days before first&#xD;
                  randomization&#xD;
&#xD;
               -  Positive C. difficile toxin B stool assay during the screening period&#xD;
&#xD;
          8. Treatment for intestinal pathogens other than C. difficile within 30 days prior to&#xD;
             first randomization&#xD;
&#xD;
          9. Other chronic systemic infections&#xD;
&#xD;
               -  History of chronic systemic infections including but not limited to tuberculosis,&#xD;
                  human immunodeficiency virus (HIV), hepatitis B or C, within 6 months before&#xD;
                  Screening&#xD;
&#xD;
               -  Positive interferon-gamma release assay (IGRAs) for Mycobacterium tuberculosis at&#xD;
                  Screening&#xD;
&#xD;
               -  Positive HBsAg (hepatitis B virus surface antigen), HBcAb (hepatitis B core&#xD;
                  antibody), positive hepatitis C virus and/or HIV-antigen-antibody (HIV-Ag/Ab)&#xD;
                  test at Screening&#xD;
&#xD;
         10. Any live vaccinations within 30 days prior to study drug administration except for the&#xD;
             influenza vaccine&#xD;
&#xD;
             Other medical history and concomitant disease exclusion criteria&#xD;
&#xD;
         11. Known history of nephrolithiasis or underlying condition with a strong association of&#xD;
             nephrolithiasis, including hereditary hyperoxaluria or hereditary hyperuricemia&#xD;
&#xD;
         12. Diagnosis or suspected liver function impairment which may cause, as assessed by the&#xD;
             investigator, a potential for fluctuating liver function tests during this trial&#xD;
&#xD;
         13. Renal impairment i.e. estimated glomerular filtration rate (eGFR) â¤60 mL/min/1.73mÂ²&#xD;
&#xD;
         14. Serum uric acid levels at Screening &gt;1.2 x ULN (for women &gt;6.8 mg/dL, for men &gt;8.4&#xD;
             mg/dL)&#xD;
&#xD;
         15. History or clinical diagnosis of gout&#xD;
&#xD;
         16. Known or suspected Gilbert syndrome&#xD;
&#xD;
         17. Indirect (unconjugated) bilirubin â¥1.2 x ULN at Screening (i.e. â¥ 1.1 mg/dL)&#xD;
&#xD;
         18. Concurrent malignancy or prior malignancy within the previous 10 years except for the&#xD;
             following: adequately-treated non-melanoma skin cancer and adequately-treated cervical&#xD;
             cancer&#xD;
&#xD;
             Therapy exclusion criteria&#xD;
&#xD;
         19. Use of any investigational product within 8 weeks or 5 x the respective half-life&#xD;
             before first randomization, whatever is longer&#xD;
&#xD;
         20. Use of the following medications within 2 weeks before first randomization:&#xD;
&#xD;
               1. Tofacitinib&#xD;
&#xD;
               2. Methotrexate,&#xD;
&#xD;
               3. Mycophenolate mofetil&#xD;
&#xD;
               4. Any calcineurin inhibitors (e.g. tacrolimus, cyclosporine, or pimecrolimus)&#xD;
&#xD;
               5. Oral systemic corticosteroids &gt;20 mg/day prednisolone equivalent including&#xD;
                  beclomethasone dipropionate (at &gt;5 mg/day) and budesonide (multi-matrix [MMX] at&#xD;
                  &gt;9 mg/day)&#xD;
&#xD;
               6. Oral aminosalicylates (e.g. mesalazines) &gt;4 g/day&#xD;
&#xD;
         21. Use of the following medications within 4 weeks before first randomization:&#xD;
&#xD;
               1. Use of intravenous corticosteroids&#xD;
&#xD;
               2. Use of thiopurines including azathioprine, mercaptopurine and 6-thioguanine&#xD;
&#xD;
               3. Use of any rectal and topical aminosalicylates and/or budesonide&#xD;
&#xD;
         22. Use of oral systemic corticosteroids â¤20 mg/day prednisolone equivalent including&#xD;
             beclomethasone dipropionate (at â¤5 mg/day) and budesonide (MMX at â¤9 mg/day) unless&#xD;
             they have been used for at least 4 weeks before first randomization and at a stable&#xD;
             dose for at least 2 weeks before first randomization&#xD;
&#xD;
         23. Oral aminosalicylates (e.g. mesalazines) â¤4 g/day unless they have been used for at&#xD;
             least 6 weeks and with a stable dose for at least 3 weeks before first randomization&#xD;
&#xD;
         24. Use of biologics as follows:&#xD;
&#xD;
               1. anti-tumor necrosis factor Î± antibodies (infliximab, adalimumab, golimumab,&#xD;
                  including their biosimilars) within 4 weeks before first randomization&#xD;
&#xD;
               2. vedolizumab and ustekinumab within 8 weeks before first randomization&#xD;
&#xD;
         25. Use of the DHODH inhibitors leflunomide or teriflunomide within 6 months before first&#xD;
             randomization&#xD;
&#xD;
         26. Any use of natalizumab (Tysabriâ¢) within 12 months before first randomization&#xD;
&#xD;
         27. Use of the following concomitant medications is prohibited at Screening and throughout&#xD;
             the duration of the trial:&#xD;
&#xD;
               -  any medication known to significantly increase urinary elimination of uric acid,&#xD;
                  in particular lesinurad (Zurampicâ¢) as well as uricosuric drugs such as&#xD;
                  probenecid&#xD;
&#xD;
               -  treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin,&#xD;
                  bosutinib, sorafenib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib&#xD;
&#xD;
               -  any drug significantly restricting water diuresis, in particular vasopressin and&#xD;
                  vasopressin analogs&#xD;
&#xD;
               -  Rosuvastatin at doses Ë10 mg/day&#xD;
&#xD;
             General exclusion criteria&#xD;
&#xD;
         28. History of, or current serious, severe, or unstable (acute or progressive) physical or&#xD;
             mental illness, or any medical condition, including laboratory anomalies or renal or&#xD;
             hepatic impairment, that may require treatment or would put the patient in jeopardy if&#xD;
             he/she was to participate in the study&#xD;
&#xD;
         29. Known hypersensitivity to DHODH inhibitors (teriflunomide, leflunomide) or any&#xD;
             ingredient of the investigational product&#xD;
&#xD;
         30. Pregnancy or breastfeeding&#xD;
&#xD;
         31. History of drug or alcohol abuse during the past year&#xD;
&#xD;
         32. Concurrent participation in any other clinical trial using an investigational&#xD;
             medicinal product or medical device&#xD;
&#xD;
         33. An employee of an investigator or sponsor or an immediate relative of an investigator&#xD;
&#xD;
        Exclusion criteria for open-label treatment extension arm&#xD;
&#xD;
          1. Any ongoing, clinically significant treatment-emergent (started during the IMU-838&#xD;
             treatment in the blinded treatment arms) adverse event (AE) or laboratory abnormality&#xD;
             (including blood chemistry and urinalysis) as assessed by the investigator *&#xD;
&#xD;
          2. Significant treatment or study non-compliance during induction and/or maintenance&#xD;
             phase (as assessed by the investigator), and/or inability or unwillingness to follow&#xD;
             instructions by study personnel as assessed by the investigator&#xD;
&#xD;
          3. Significant protocol deviations during induction and/or maintenance phase that are&#xD;
             assessed by the investigator to negatively affect further patient cooperation in this&#xD;
             study&#xD;
&#xD;
               -  If treatment-emergent AEs are the reason for exclusion from the open-label&#xD;
                  extension arm, the eligibility can be re-assessed up to 30 days following the&#xD;
                  last treatment in the blinded treatment arms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Muehler</last_name>
    <role>Study Director</role>
    <affiliation>Immunic Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Del Sol Research Management, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Medical Research, LLC</name>
      <address>
        <city>Lighthouse Point</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medley Research Associates</name>
      <address>
        <city>Medley</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Life Research LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155-4630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Clinical Trials</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026-3240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, P.C.</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Clinical Studies</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury, LLC</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406-7132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Street Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Health Specialists</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durres Regional Hospital</name>
      <address>
        <city>Durres</city>
        <zip>2001</zip>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital of Shkoder</name>
      <address>
        <city>Shkoder</city>
        <zip>4001</zip>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Mother Teresa</name>
      <address>
        <city>Tirana</city>
        <zip>1000</zip>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gomel Regional Clinical Hospital</name>
      <address>
        <city>Gomel</city>
        <zip>246029</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Center for Radiation Medicine and Human Ecology</name>
      <address>
        <city>Gomel</city>
        <zip>246040</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitiebsk State Order of Peoples' Friendship Medical University</name>
      <address>
        <city>Vitebsk</city>
        <zip>210009</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre of the Republic of Srpska, Internal Medicine Clinic, Department of Gastroenterology and Hepatology</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Hospital Mostar, Internal Medicine Clinic, Department of Gastroenterology</name>
      <address>
        <city>Mostar</city>
        <zip>88000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Blagoevgrad AD</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mhat Byala</name>
      <address>
        <city>Byala</city>
        <zip>187100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Dr. Hristo Stambolski&quot; EOOD</name>
      <address>
        <city>Kazanlak</city>
        <zip>6100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Medconsult Pleven&quot; OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Exacta Medica</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot; EAD, Plovdiv, Gastroenterology clinic</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Hera&quot; EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1510</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic-Consulting Center &quot;Convex&quot; EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Bjelovar</name>
      <address>
        <city>Bjelovar</city>
        <zip>43000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Rijeka</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Split</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Vukovar</name>
      <address>
        <city>Vukovar</city>
        <zip>32000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic Solmed Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Split</name>
      <address>
        <city>Zagreb</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asclepiades - Interna a gastroenterologie s.r.o. - HavÃ­Åov</name>
      <address>
        <city>HavÃ­Åov</city>
        <zip>73601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK, s.r.o. Poliklinika III</name>
      <address>
        <city>Hradec KrÃ¡lovÃ©</city>
        <zip>50012</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artroscan s.r.o.</name>
      <address>
        <city>Ostrava - TÅebovice</city>
        <zip>72200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FaraCol s.r.o. - Prague</name>
      <address>
        <city>Praha</city>
        <zip>10100</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICON a.s. - Poliklinika BudÄjovickÃ¡ Gastroenterologie</name>
      <address>
        <city>Praha</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika ResTrial</name>
      <address>
        <city>Praha</city>
        <zip>14300</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VÅ¡eobecnÃ¡ fakultnÃ­ nemocnice v Praze IV. internÃ­ klinika VFN a 1. LF UK</name>
      <address>
        <city>Praha</city>
        <zip>17004</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academician Z.Tskhakaia West Georgia National Center of Interventional Medicine</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Unimedi Kakheti - Caraps Medline</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-TweeSteden Hospital</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City General Hospita 8th September</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic for Hematology - Skopje - Macedonian Hematology Association</name>
      <address>
        <city>Skopje</city>
        <zip>1131</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum UsÅug Medycznych MaxMed</name>
      <address>
        <city>Bochnia</city>
        <zip>32700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Gdynia</name>
      <address>
        <city>Gdynia</city>
        <zip>81338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Endo-med Sp. z o.o.</name>
      <address>
        <city>Karczew</city>
        <zip>05480</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Longa Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <zip>40748</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GLOBE Badania Kliniczne Sp. z o.o.</name>
      <address>
        <city>KÅodzko</city>
        <zip>57300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie OddziaÅ Gastroenterologii</name>
      <address>
        <city>Lublin</city>
        <zip>20954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZakÅad leczniczy ALLMEDICA BADANIA KLINICZNE Sp. z o.o. Sp. K.</name>
      <address>
        <city>Nowy Targ</city>
        <zip>34400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etyka OÅrodek BadaÅ Klinicznych</name>
      <address>
        <city>Olsztyn</city>
        <zip>10117</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ars Medical - Szpital, Ars Medical - Ambulatorium</name>
      <address>
        <city>PiÅa</city>
        <zip>64920</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOLUMED Centrum Medyczne</name>
      <address>
        <city>PoznaÅ</city>
        <zip>60529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny ZakÅad Opieki Zdrowotnej Centrum Medyczne HCP - Lecznictwo Stacjonarne</name>
      <address>
        <city>PoznaÅ</city>
        <zip>61485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Medifem</name>
      <address>
        <city>Warszawa</city>
        <zip>02-884</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badawcze WspÃ³Åczesnej Terapii, Prywatny Gabinet Lekarski dr Anna Bochenek-Mularczyk</name>
      <address>
        <city>Warszawa</city>
        <zip>02679</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Vistamed</name>
      <address>
        <city>Wroclaw</city>
        <zip>53149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne OMNI Clinic Sp. z o.o. SpÃ³Åka Komandytowa</name>
      <address>
        <city>WrocÅaw</city>
        <zip>54204</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Med-Gastr Sp. z o.o. SpÃ³Åka Komandytowa</name>
      <address>
        <city>ÅÃ³dz</city>
        <zip>91034</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salve Medica Sp. z o.o. SpÃ³Åka Komandytowa</name>
      <address>
        <city>ÅÃ³dÅº</city>
        <zip>91211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e UniversitÃ¡rio de Coimbra, EPE - Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Senhora da Oliveira - GuimarÃ£es, EPE</name>
      <address>
        <city>GuimarÃ£es</city>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Entre o Douro e Vouga, EPE - Hospital SÃ£o SebastiÃ£o</name>
      <address>
        <city>Santa Maria da Feira</city>
        <zip>4520-211</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. MEDLIFE S.A., Sectia Gastroenterologie</name>
      <address>
        <city>Bucharest</city>
        <zip>10719</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Colentina, Sectia Gastroenterologie</name>
      <address>
        <city>Bucharest</city>
        <zip>20125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni, Sectia Clinica Gastroenterologie III</name>
      <address>
        <city>Bucharest</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Cabinet Particular Policlinic Algomed SRL, Specialitatea Gastroenterologie</name>
      <address>
        <city>Timisoara</city>
        <zip>300002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEI HPE &quot;Kuban State Medical University&quot; of MoH and SD, CBHS Regional Clinical Hospital No.2</name>
      <address>
        <city>Krasnodar</city>
        <zip>350072</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Russian Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Medical Biophysical Center n.a. Burnazyan</name>
      <address>
        <city>Moscow</city>
        <zip>123098</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institution of Moscow Region named after M. F. Vladimirsky</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirskiy Gastrocenter, LLC</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBEI HE &quot;Military Medical Academy n.a. S.M. Kirov&quot; under the Ministry of Defence of Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Saint Martyr Elizaveta</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Eco-Safety, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterological Center &quot;Expert&quot; LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196620</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Medical University named after I.P. Pavlov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital No. 5 - Sochi</name>
      <address>
        <city>Sochi</city>
        <zip>354207</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siberian State Medical University</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Autonomous Healthcare Institution &quot;Tomsk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for gastroenterohepatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Bezaniska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Leskovac</name>
      <address>
        <city>Leskovac</city>
        <zip>16000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Djordje Joanovic, Internal Deases Department, Gastroenterology</name>
      <address>
        <city>Zrenjanin</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan RamÃ³n Jimenez</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BezmiÃ¢lem VakÄ±f Ãniversitesi</name>
      <address>
        <city>Fatih</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi Gastroenteroloji Bilim Dali</name>
      <address>
        <city>Fatih</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik Ãniversitesi Tip Fakultesi</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Enterprise &quot;Dnipropetrovsk regional clinical hospital named after I.I. Mechnikova&quot;, Department of Gastroenterology (Hepatology)</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MNPE &quot;Regional Clinical Hospital of Ivano-Frankivsk Regional Council&quot;, Gastroenterology Department, SHEI &quot;Ivano-Frankivsk National Medical University&quot;, Chair of Internal Medicine #1</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk City Clinical Hospital No. 1</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;City Clinical Hospital #2 named after prof. O.O. Shalimova&quot;, of Kharkiv City Council, Proctology Department</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise of Kharkiv Regional Council &quot;Regional Clinical Hospital&quot;, Gastroenterology Department</name>
      <address>
        <city>Kharkiv</city>
        <zip>61201</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Enterprise Private Manufacturing Firm &quot;Acinus&quot;, Treatment and diagnostic Centre</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Medical Clinic Blagomed LLC</name>
      <address>
        <city>Kyiv</city>
        <zip>01001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #18, Proctology Department, National Medical University named after O.O.Bogomolets, Chair of Surgery #1</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #1, Therapeutics Department #2</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre of Limited Liability Company &quot;Medical Centre &quot;Dopomoga plus&quot;&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>02132</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shalimov's National Institute of surgery and transplantation</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre of Limited Liability Company &quot;Medical Centre &quot;Consilium Medical&quot;, clinico-consultation department</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Regional Clinical Hospital No 2</name>
      <address>
        <city>Kyiv</city>
        <zip>04073</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <zip>43000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise of Lviv Regional Council &quot;Lviv Regional Clinical Hospital&quot;, proctology department, Danylo Galytsky Lviv National Medical University, Chair of Surgery #1</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KARDIOKOM Ltd.</name>
      <address>
        <city>Mykolaiv</city>
        <zip>08711</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Transcarpathian Regional Clinical Hospital named after Andriy Novaka, gastroenterology department</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;Vinnytsia Regional Clinical Hospital named after M.I. Pyrogova of Vinnytsia Regional Council, Regional Specialized Clinical Gastroenterological Center,</name>
      <address>
        <city>Vinnytsia</city>
        <zip>20128</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;Vinnytsia City Clinical Hospital #1, Gastroenterology Department, Vinnytsia National Medical University named after M.I.Pyrogova, Chair of Propaedeutics of Internal Medicine</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Zaporizhzhska Regional Clinical Hospital&quot; of Zaporizhzha Regional Council, gastroenterology department</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London North West University Healthcare NHS Trust (LNWH), St Mark's Hospital, R&amp;D Department, Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust, of Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Helens &amp; Knowsley Teaching Hospitals NHS Trust, Whiston Hospital</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire NHS Trust, University Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shrewsbury and Telford Hospitals NHS Trust, Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Trust, New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Belarus</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Netherlands</country>
    <country>North Macedonia</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211431.pdf</url>
    <description>European Medicines Agency (EMA). Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis.[Online]. 2016.</description>
  </link>
  <link>
    <url>https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM515143.pdf</url>
    <description>US Food and Drug Administration (FDA). Ulcerative Colitis: Clinical Trial Endpoints. Guidance for Industry.[Online]. 2016.</description>
  </link>
  <link>
    <url>http://www.auanet.org/guidelines/asymptomatic-microhematuria</url>
    <description>American Urological Association. Guideline: Diagnosis, evaluation and follow up of asymptomatic mircrohematuria. (AMH) in adults.[Online]. 2012.</description>
  </link>
  <link>
    <url>http://eurlex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A31995L0046</url>
    <description>European Union (EU). Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. [Online].</description>
  </link>
  <link>
    <url>http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016R0679</url>
    <description>EU. Regulation 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). 2016; [Online].</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>IMU-838</keyword>
  <keyword>vidofludimus calcium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

